GAVRETO ®(pralsetinib) capsules
RGL-RET-001
Approved small_molecule active
Quick answer
GAVRETO ®(pralsetinib) capsules for Patients with advanced or metastatic solid tumors is a Approved program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RIGEL PHARMACEUTICALS INC
- Indication
- Patients with advanced or metastatic solid tumors
- Phase
- Approved
- Modality
- small_molecule
- Status
- active